Kristina Callis Duffin Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

1/2024	Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry.
2/2023	Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
2/2023	Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
1/2023	The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
1/2022	Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
1/2022	Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.
3/2021	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting.
3/2021	Pustular Psoriasis and Associated Musculoskeletal Disorders.
1/2021	Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
1/2021	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kristina Callis Duffin Research Topics

Disease

28	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2024 - 04/2009
10	Psoriatic Arthritis 01/2022 - 04/2009
2	Fatigue 01/2024 - 06/2018
2	Diarrhea 01/2022 - 08/2017
2	Nausea 01/2022 - 08/2017
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 08/2017
2	Headache (Headaches) 01/2022 - 08/2017
1	Pain (Aches) 01/2024
1	Skin Diseases (Skin Disease) 01/2024
1	Overweight 01/2023
1	Nasopharyngitis 01/2022
1	Chronic Disease (Chronic Diseases) 06/2018
1	Vomiting 08/2017
1	Musculoskeletal Diseases (Musculoskeletal Disease) 01/2016
1	Neutropenia 10/2015
1	Candidiasis (Moniliasis) 10/2015
1	Body Weight (Weight, Body) 10/2015

Drug/Important Bio-Agent (IBA)

4	guselkumabIBA 02/2023 - 01/2022
4	Methotrexate (Mexate)FDA LinkGeneric 06/2020 - 04/2012
3	Interleukin-23 (Interleukin 23)IBA 01/2024 - 02/2012
3	Immunoglobulin A (IgA)IBA 02/2023 - 01/2023
3	Monoclonal AntibodiesIBA 01/2016 - 02/2012
3	Ustekinumab (CNTO 1275)FDA Link 10/2015 - 02/2012
3	Etanercept (Enbrel)FDA Link 12/2014 - 04/2012
2	apremilastIBA 01/2022 - 08/2017
2	Biomarkers (Surrogate Marker)IBA 06/2018 - 01/2016
2	Adalimumab (Humira)FDA Link 12/2014 - 04/2012
1	risankizumabIBA 01/2024
1	COVID-19 VaccinesIBA 03/2021
1	Biocompatible Materials (Biomaterials)IBA 06/2020
1	tofacitinibIBA 01/2019
1	Prostaglandins AIBA 01/2019
1	Biosimilar PharmaceuticalsIBA 06/2018
1	ametantrone (HAQ)IBA 06/2018
1	Proteins (Proteins, Gene)FDA Link 11/2017
1	MicroRNAs (MicroRNA)IBA 02/2016
1	ixekizumabIBA 01/2016
1	Interleukin-17 (Interleukin 17)IBA 01/2016
1	brodalumabIBA 10/2015
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 12/2014
1	Acitretin FDA Link 12/2014
1	Infliximab (Remicade)FDA Link 12/2014
1	Clobetasol (Clobetasol Propionate)FDA LinkGeneric 09/2013
1	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2013
1	Interleukin-12 (IL 12)IBA 02/2012

Therapy/Procedure

16	Therapeutics 01/2024 - 04/2009
4	Biological Therapy 02/2023 - 01/2016
4	Phototherapy (Light Therapy) 01/2017 - 03/2012
1	Drug Therapy (Chemotherapy) 03/2021
1	Precision Medicine 06/2020
1	Retreatment 01/2019
1	Injections 01/2016
1	Subcutaneous Injections 01/2016